Comparison of the Protective Effects of Nebivolol and Metoprolol against LPS-Induced Injury in H9c2 Cardiomyoblasts.
LPS
beta-blockers
metoprolol
mitochondrial dysfunction
nebivolol
oxidative stress
Journal
Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
received:
02
10
2023
revised:
31
10
2023
accepted:
03
11
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
Here, we, for the first time, compared the cardioprotective effects of third-generation vasodilating beta-blocker nebivolol (Neb) and conventional beta-blocker metoprolol (Met) on LPS-induced injury in H9c2 cardiomyoblasts. Our findings denoted that Neb and Met pretreatment diminish LPS-mediated cytotoxicity and oxidative stress. Concomitantly, LPS-triggered inflammatory cytokines activation was significantly suppressed by Neb but not by Met. Pretreatment with either Neb or Met alleviated LPS-mediated mitochondrial impairment by enhancing the expression of genes related to its biogenesis such as PGC-1α, NRF1, and TFAM. On the contrary, Neb but not Met-upregulated mitochondrial fusion-related genes such as OPA, and MFN2. In summary, our findings suggest that Neb and Met treatment significantly ameliorated the LPS-induced cytotoxicity and oxidative stress. Additionally, these findings suggest that Neb but not Met significantly down-regulates LPS-induced proinflammatory factors, probably by enhancing mitochondrial biogenesis and fusion.
Identifiants
pubmed: 37998760
pii: cimb45110583
doi: 10.3390/cimb45110583
pmc: PMC10670410
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9316-9327Subventions
Organisme : King Abdulaziz City for Science and Technology
ID : 14- BIO688-02
Références
Hypertens Res. 2018 Apr;41(4):253-262
pubmed: 29449707
Intensive Care Med. 2016 Oct;42(10):1607-1609
pubmed: 27349239
Cardiovasc Drugs Ther. 2022 Oct;36(5):959-971
pubmed: 34106365
J Pharm Pharmacol. 2021 Oct 7;73(11):1520-1529
pubmed: 34453839
Hypertension. 2010 Apr;55(4):880-8
pubmed: 20176997
PLoS One. 2013 Aug 20;8(8):e71980
pubmed: 23977191
Scand J Clin Lab Invest. 2012 Sep;72(5):427-32
pubmed: 22708640
Arch Cardiovasc Dis. 2013 Dec;106(12):672-9
pubmed: 24070595
J Intensive Care Med. 2008 May-Jun;23(3):178-83
pubmed: 18443011
Cell Biosci. 2020 May 24;10:72
pubmed: 32489586
Clin Drug Investig. 2015 Nov;35(11):707-16
pubmed: 26387030
JAMA. 2013 Oct 23;310(16):1683-91
pubmed: 24108526
Dose Response. 2019 May 20;17(2):1559325819847409
pubmed: 31205455
J Am Coll Cardiol. 2015 Feb 24;65(7):668-80
pubmed: 25677428
Pharmacol Res. 2021 Oct;172:105802
pubmed: 34363948
J Intensive Med. 2022 Apr 03;2(3):150-155
pubmed: 36789018
Eur Heart J. 2020 Dec 7;41(46):4425-4440
pubmed: 33026079
Cells. 2021 Apr 06;10(4):
pubmed: 33917391
Auton Neurosci. 2021 Sep;234:102832
pubmed: 34126326
Biochem Biophys Res Commun. 2013 Aug 16;438(1):211-7
pubmed: 23886954
Cardiovasc Ther. 2008 Fall;26(3):189-202
pubmed: 18786089
Curr Issues Mol Biol. 2022 May 10;44(5):2139-2152
pubmed: 35678673
PLoS One. 2019 Apr 9;14(4):e0214740
pubmed: 30964911
Crit Care Med. 2015 Oct;43(10):2104-11
pubmed: 26154932
Ann Med. 2018 Mar;50(2):121-127
pubmed: 29237304
Indian J Pharmacol. 2014 Sep-Oct;46(5):485-9
pubmed: 25298575
Am J Physiol Heart Circ Physiol. 2012 Jun 1;302(11):H2341-51
pubmed: 22447938
Cold Spring Harb Protoc. 2016 Apr 01;2016(4):pdb.prot087379
pubmed: 27037069
Obesity (Silver Spring). 2015 Nov;23(11):2251-9
pubmed: 26381051